scPharmaceuticals - SCPH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 441.31%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.51
▼ -0.01 (-0.28%)

This chart shows the closing price for SCPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New scPharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCPH

Analyst Price Target is $19.00
▲ +441.31% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for scPharmaceuticals in the last 3 months. The average price target is $19.00, with a high forecast of $20.00 and a low forecast of $18.00. The average price target represents a 441.31% upside from the last price of $3.51.

This chart shows the closing price for SCPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in scPharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
9/7/2023Craig HallumInitiated CoverageBuy$20.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
8/2/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
5/11/2023Maxim GroupBoost Target$13.00 ➝ $20.00Low
3/23/2023HC WainwrightReiterated RatingBuy$18.00Low
1/27/2023SVB LeerinkBoost TargetOutperform$12.00 ➝ $13.00Low
12/1/2022CowenInitiated CoverageOutperform$25.00Low
12/1/2022CowenInitiated CoverageOutperform$25.00N/A
11/10/2022SVB LeerinkBoost TargetOutperform$11.00 ➝ $12.00Low
11/10/2022HC WainwrightBoost TargetBuy$15.00 ➝ $18.00Low
10/21/2022Jefferies Financial GroupInitiated CoverageBuy$14.00Low
10/11/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$6.00 ➝ $11.00Low
10/11/2022Maxim GroupBoost Target$10.00 ➝ $13.00Low
8/2/2022Maxim GroupInitiated CoverageBuy$10.00Low
7/13/2022HC WainwrightReiterated RatingBuy$15.00Low
5/17/2022SVB LeerinkBoost TargetMarket Perform$6.00Low
4/12/2022HC WainwrightReiterated RatingBuy$15.00Medium
1/21/2022SVB LeerinkReiterated RatingHold$5.00Low
9/9/2021SVB LeerinkInitiated CoverageMarket Perform$6.00High
7/2/2021HC WainwrightReiterated RatingBuy$15.00Low
12/8/2020BMO Capital MarketsLower TargetPositive ➝ Outperform$13.00 ➝ $10.00High
11/30/2020SVB LeerinkBoost TargetMarket Perform$11.00 ➝ $12.00High
6/23/2020BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform$14.00High
5/27/2020SVB LeerinkLower TargetMarket Perform$12.00 ➝ $10.00Low
5/13/2020SVB LeerinkBoost TargetMarket Perform$7.00 ➝ $12.00Medium
5/13/2020HC WainwrightReiterated RatingBuy$13.00 ➝ $15.00Medium
10/15/2019HC WainwrightInitiated CoverageBuy$13.00Medium
(Data available from 5/25/2019 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/26/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 8 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/25/2024

Current Sentiment

  • 8 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
scPharmaceuticals logo
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $3.51
Low: $3.39
High: $3.79

50 Day Range

MA: $4.70
Low: $3.51
High: $5.58

52 Week Range

Now: $3.51
Low: $3.24
High: $11.75

Volume

370,196 shs

Average Volume

272,841 shs

Market Capitalization

$126.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.09

Frequently Asked Questions

What sell-side analysts currently cover shares of scPharmaceuticals?

The following equities research analysts have issued stock ratings on scPharmaceuticals in the last year: Craig Hallum, and HC Wainwright.
View the latest analyst ratings for SCPH.

What is the current price target for scPharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for scPharmaceuticals in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 441.3%. Craig Hallum has the highest price target set, predicting SCPH will reach $20.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $18.00 for scPharmaceuticals in the next year.
View the latest price targets for SCPH.

What is the current consensus analyst rating for scPharmaceuticals?

scPharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SCPH will outperform the market and that investors should add to their positions of scPharmaceuticals.
View the latest ratings for SCPH.

What other companies compete with scPharmaceuticals?

How do I contact scPharmaceuticals' investor relations team?

scPharmaceuticals' physical mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company's listed phone number is (617) 517-0730 and its investor relations email address is [email protected]. The official website for scPharmaceuticals is www.scpharma.com. Learn More about contacing scPharmaceuticals investor relations.